Leukotrienes in respiratory disease

Area of Science:

• Biochemistry
• Pharmacology
• Respiratory Medicine

Background:

• Arachidonic acid metabolism produces leukotrienes, including leukotriene B(4) and cysteinyl leukotrienes (LTC4, LTD4, LTE4).
• Leukotrienes are implicated in asthma pathogenesis, with elevated levels observed in the lungs after antigen exposure.
• Cysteinyl leukotrienes are responsible for the bronchoconstriction previously known as slow-reacting substance of anaphylaxis.

Purpose of the Study:

• To review the development and clinical efficacy of leukotriene modulators for asthma treatment.
• To evaluate the role of leukotriene B(4) and cysteinyl leukotrienes in respiratory conditions.
• To assess the impact of approved leukotriene-targeting drugs on asthma management.

Main Methods:

• Review of clinical data from approved leukotriene modulators: zafirlukast, montelukast, pranlukast (cysteinyl leukotriene antagonists), and zileuton (5-lipoxygenase inhibitor).
• Analysis of drug efficacy in improving lung function and reducing asthma symptom scores.
• Evaluation of the proposed mechanism of action, focusing on interference with cysteinyl leukotrienes.

Main Results:

• Leukotriene modulators demonstrate rapid and sustained improvements in lung function and asthma symptom scores.
• Clinical benefits are primarily attributed to the antagonism of cysteinyl leukotrienes.
• No significant clinical data support a major role for leukotriene B(4) in human asthma.

Conclusions:

• Leukotriene modulators, particularly cysteinyl leukotriene antagonists, represent a significant advancement in oral asthma therapy.
• These drugs provide a valuable therapeutic option for respiratory physicians, setting a benchmark for new anti-inflammatory treatments.
• Further investigation of 5-lipoxygenase inhibitors in COPD, characterized by neutrophil infiltration, is warranted due to the potential role of leukotriene B(4).